| 000 | 03618cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032008.0 | ||
| 008 | 180521s2017 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2017.Ma.O | ||
| 100 | 0 | _aMaha Alaa Eldin Abdelfatah | |
| 245 | 1 | 0 |
_aOutcome of treatment of multiple myeloma patients with bortezomib-based regimens compared to vincristine,doxorubicin and dexamethasone (VAD) regimen / _cMaha Alaa Eldin Abdelfatah ; Supervised Mohamed Abdelmooti , Omar Elfarouk Osman Zaki , Mosaad Mahmoud Elgammal |
| 246 | 1 | 5 | _aنتائج علاج الميلوما المتعددة باستخدام البروتوكولات المحتوية على البورتزيماب مقارنة باستخدام البروتوكول المحتوي على الفينكرستين والدوكسوربسين والديكساميثازون |
| 260 |
_aCairo : _bMaha Alaa Eldin Abdelfatah , _c2017 |
||
| 300 |
_a121 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical ) | ||
| 520 | _aObjective: Compare outcome of treatment of Bortezomib-based regimens versus VAD regimen (Vincristine, Doxorubicin, Dexamethazone) in multiple myeloma patients treated in The Medical Oncology departments of both National Cancer Institute (NCI) and Nasser Institute from January 2011 till December 2015). Methods:This study was performed retrospectively on 89 MM patientstreated at The Medical Oncology departments of both National Cancer Institute (NCI) and Nasser Institute from January 2011 till December 2015.All patients were evaluated for different responses with different lines of treatment (VAD versus Bortezomib based regimens) which correlated with progression free survival (PFS) and overall survival (OS). Also, the different prognostic factors: age, sex, clinical presentation, albumin, LDH, creatinine,B2 microglobulin, ISS, Durie Salmon Staging and ASCT which correlated with different lines of treatment, PFS and OS. Results: The age of patients ranged between 32 years to 76 years and the mean age was 51.1+/-7.4 years. It included 65.2% males and 34.8% females with male to female ratio 1.87:1. Bony pains were the most common clinical manifestation of patients in our study (44.9%) followed by bony masses (22.5%), fractures (16.9%), pallor (7.9%), neurological symptoms (5.6%) and finally oliguria (2.2%).Bortezomib based regimens have better overall response rate (ORR)({u2265}PR)( p value 0.031), progression free survival PFS(p value 0.004) and disease free survival DFS(p value 0.013) as 1st line treatment compared to VAD regimen. Also in previously treated patients bortezomib based regimens showed better progression free survival PFS(p value 0.039) compared to VAD regimen. There was significant relation between age (p value 0.001&<0.001) and ASCT (p value 0.001&0.034) with PFS and OS respectively, while other factors was not significant including (sex, clinical presentation, B2 microglobulin, creatinine, LDH, albumin, ISS, Durie Salmon Staging) | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aBortezomib based regimens | |
| 653 | 4 | _aMultiple Myeloma | |
| 653 | 4 | _aVAD regimen | |
| 700 | 0 |
_aMohamed Abdelmooti , _eSupervisor |
|
| 700 | 0 |
_aMosaad Mahmoud Elgammal , _eSupervisor |
|
| 700 | 0 |
_aOmar Elfarouk Osman Zaki , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c66278 _d66278 |
||